Work

Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.7029

Authors: Ryan Daniel Cassaday, Daniel J. DeAngelo, Giovanni Martinelli, Wendy Stock, Matthias Stelljes, Nicola Gökbuget, Anjali S. Advani, Susan Mary O'Brien, Michaela Liedtke, Akil Abid Merchant, Tao Wang, Erik Vandendries, David I. Marks, Elias Jabbour, Hagop M. Kantarjian

Institutions: University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, University of Chicago, University Hospital Münster, Goethe University Frankfurt, Cleveland Clinic, University of California, Irvine, Stanford Medicine, Stanford University, University of Southern California, Pfizer (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890085656

Cites:

Cited by: 1

Related to: 10